Craig Malzahn's most recent trade in Regenxbio Inc was a trade of 65,847 Common Stock done . Disclosure was reported to the exchange on Jan. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Craig Malzahn | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 65,847 | 82,194 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Craig Malzahn | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 35,402 | 35,402 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Craig Malzahn | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.40 per share. | 02 Jan 2026 | 1,238 | 16,347 (0%) | 0% | 14.4 | 17,827 | Common Stock |
| Regenxbio Inc | Craig Malzahn | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.93 per share. | 01 Sep 2025 | 234 | 17,585 (0%) | 0% | 8.9 | 2,090 | Common Stock |